SEC Looks to Revoke Securities Registration of Medfield Biotech Co.

The Securities and Exchange Commission is looking to revoke a Medfield biotech company's securities registration after it failed to file a quarterly report. 

Symbollon Pharmaceuticals, which reportedly develops iodine-based agents, had not filed with the SEC since May 2011, according to the Boston Business Journal. 

Moreover, the SEC plans to hold a public hearing on Symbollon's status as a publicly-traded company, according to BBJ. To read the SEC's notice of the hearing, click here. 

For more on Symbollon, head over to the Boston Business Journal >>